Open AccessExtended-Release Physostigmine in Alzheimer Disease
Author(s) -
Christopher H. van Dyck
Publication year - 2000
Publication title -
archives of general psychiatry
Language(s) - English
Resource type - Journals
eISSN - 1538-3636
pISSN - 0003-990X
DOI - 10.1001/archpsyc.57.2.157
Subject(s) - physostigmine , placebo , nausea , clinical global impression , psychology , alzheimer's disease , medicine , anesthesia , disease , pathology , alternative medicine , acetylcholine
The efficacy of extended-release physostigmine salicylate, an acetylcholinesterase inhibitor, was evaluated in 850 subjects with mild-to-moderate Alzheimer disease (AD) in a multicenter trial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom